Vandetanib as a potential new treatment for estrogen receptor-negative breast cancers-Reference-Cited by-同舟云学术

Vandetanib as a potential new treatment for estrogen receptor-negative breast cancers

Published:2016-01-06 Issue:10 Volume:138 Page:2510-2521
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Hatem Rana¹²,Labiod Dalila³,Château-Joubert Sophie⁴,de Plater Ludmilla³,El Botty Rania³,Vacher Sophie¹,Bonin Florian¹,Servely Jean-Luc⁴⁵,Dieras Véronique⁶,Bièche Ivan¹,Marangoni Elisabetta³

Affiliation:

1. Genetics Department; Hospital, Institut Curie; Paris 75005 France

2. Faculty of Pharmacy; Aleppo University; Aleppo Syria

3. Translational Research Department; Institut Curie; Paris 75005 France

4. BioPôle Alfort; National Veterinary School of Alfort; 7, Av. Du Général De Gaulle, 94704 Maisons Alfort France

5. PHASE Department; INRA; Nouzilly France

6. Medical Oncology Department; Institut Curie; Paris 75005 France

Funder

Institut Curie

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/ijc.29974/fullpdf

Reference33 articles.

1. Comprehensive molecular portraits of human breast tumours;Nature,2012

2. RET in breast cancer: functional and therapeutic implications;Morandi;Trends Mol Med,2011

3. Targeting RET receptor tyrosine kinase activation in cancer;Phay;Clin Cancer Res,2010

4. Vandetanib, a novel multitargeted kinase inhibitor, in cancer therapy;Sathornsumetee;Drugs Today (Barc),2006

5. Vandetanib: first global approval;Commander;Drugs,2011

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pancreatic Stromal Cell-derived Oncostatin M Confers Drug Resistance to a Multi-tyrosine Kinase Inhibitor in Pancreatic Cancer Cells;Anticancer Research;2023-05-29

2. RET signaling in breast cancer therapeutic resistance and metastasis;Breast Cancer Research;2023-03-14

3. Drugging Hijacked Kinase Pathways in Pediatric Oncology: Opportunities and Current Scenario;Pharmaceutics;2023-02-16

4. The ixabepilone and vandetanib combination shows synergistic activity in docetaxel-resistant MDA-MB-231 breast cancer cells;Pharmacological Reports;2022-07-30

5. RET signaling pathway and RET inhibitors in human cancer;Frontiers in Oncology;2022-07-25